1. Addition of biomarker high sensitivity troponin I (hSTROPI) to QRISK3 score in predicting significant coronary artery disease (CAD). (25th November 2020) Authors: Dasari, B.C.A; Oomman, A; Govindarajulu, P; Narra, L; Mao, R; Gunasekaran, S; Satish, S; Showkathali, R; Immaneni, S; Pramodkumar, K.P; Reddy, Y.V.C; Nayak, R Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022) Authors: Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Packer, M; Anker, S; Butler, J; ... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗